New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 25, 2014
06:06 EDTIMUCImmunoCellular granted orphan drug designation for ICT-107 by EMA
ImmunoCellular Therapeutics announced that the European Medicines Agency, or EMA, has granted orphan drug designation for ICT-107 for the treatment of patients with glioblastoma. Granting of orphan drug status in the EU provides sponsor companies with incentives, including a 10-year period of market exclusivity, access to a centralized review process, trial design assistance and scientific advice during product development, fee reductions, and tax incentives. ImmunoCellular has previously received orphan designation for ICT-107 in glioblastoma in the US.
News For IMUC From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 19, 2015
09:20 EDTIMUCOn The Fly: Pre-market Movers
Subscribe for More Information
06:12 EDTIMUCImmunoCellular signs manufacturing agreement with Pharmacell B.V.
ImmunoCellular established an agreement with PharmaCell B.V. to provide contract manufacturing services for the European production of ICT-107, a dendritic cell-based cancer immunotherapy in development as a potential treatment for glioblastoma. This agreement with PharmaCell, a European contract manufacturing organization, focuses on the production of human cell therapy products, and is designed to enable ImmunoCellular to access phase 3 supplies of ICT-107, manufactured with ImmunoCellular's commercial-ready production process. ImmunoCellular intends to initiate a Phase 3 registrational program for ICT-107 in the US and in Europe in 2015.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use